Advertisement

Serum Institute of India News

alt
Cyrus Poonawalla founded the Serum Institute of India (SII) in 1966, which is today the world's largest vaccine manufacturer.
alt
Amid an alarming surge of Covid-19 cases in China, the CEO and founder of Serum Institute of India Adar Ponawalla in a tweet has urged the people not to panic. Serum Institute of India is the one who made Covishield covid vaccine. 
alt
We must continue to trust and follow the guidelines set by the Government of India, Serum Institute of India (SII) CEO Adar Poonawalla said as he expressed concern over reports of a rising COVID-19 graph in China.
alt
"Since December 2021, we have stopped the production of the Covishield vaccine. We had a stock of a few hundred million doses at that time and of that 100 million doses had already expired," Poonawalla said. 
alt
One of the directors of the SII received WhatsApp messages from a person who posed as Adar Poonawalla. The sender asked him to transfer money to certain bank accounts immediately. Believing that it was the CEO who had messaged, the company officials transferred Rs 1.01 crore.
alt
A man has filed a petition seeking a response from the makers of Covishield claiming that the vaccine caused his daughter's death He has demanded a compensation of Rs 1,000 crore from the Indian-vaccine maker Serum Institute of India (SII)
alt
 "The Subject Expert Committee of Drugs Controller General Of India (DCGI) has recommended Serum Institute of India`s (SII) vaccine Covovax for children in the age group of 7-11 years," sources said. 
alt
Serum Institute of India is considering setting up its first manufacturing plant in Africa World`s biggest vaccine maker looks to expand globally after its success in selling Covid-19 shots. 'It`s never been a better time to be a vaccine manufacturer,' SII CEO Adar Poonawalla said at the World Economic Forum.
alt
Adar Poonawalla clarified that the Covid-19 vaccine Covovax is available for everyone above the age of 12 years. Earlier, on Tuesday, SII CEO had informed that Covovax (Novavax) is now available for children in India.
alt
Covovax was approved by India's drug regulator for restricted use in emergency situations in adults on December 28. India began inoculating children aged 12-14 from March 16. Biological E's Corbevax is being used to inoculate them.
alt
The DCGI office had granted SII permission to manufacture and stock Covovax on May 17 The World Health Organisation had on December 17 issued emergency use listing for Covovax
alt
Adar Poonawalla announced the news on Twitter The vaccine is named CovovaxTM
alt
The Serum Institute of India is the first Indian company to seek approval for the COVID-19 booster dose. The new Omicron variant was first reported to the WHO by South Africa on November 24.
alt
SII cited adequate stock of the vaccine in the country and a demand for a booster.
alt
The first consignment of Covishield has already left Pune COVAX is an international COVID-19 vaccine sharing platform India will start contributing to COVAX after 8 months
alt
SII has urged the Centre to fast-track movement of Covishield domestically and globally. SII can export 50 Lakh doses of Covishield under COVAX.
alt
Moderna will become the fourth vaccine to be available for use in India The Centre plans to provide the Moderna doses directly to states Pfizer will supply one billion doses to India within this year
alt
About 5 million people in Britain are thought to have had the vaccine made by Serum Institute in India India saw a single-day rise of 46,617 new coronavirus infections The death toll due to COVID-19 rose to 4,00,312 with 853 daily fatalities
alt
Govt panel has said no to Covovax trial by SII The panel has asked it to Complete trials on adults first
alt
SII gets DCGI nod to manufacture Sputnik V It has collaborated with Moscow's Gamaleya Research Institute of Epidemiology and Microbiology It will manufacture vaccines at its Hadapsar facility






Loading...
english news
NEWS ON ONE CLICK